霍奇金淋巴瘤中的PET/CT:进展更新
18F-FDG-PET/CT已整合进霍奇金淋巴瘤的检查和治疗管理,目前常规用于分期和末次治疗后的疗效评估。中期PET/CT通常在6-8周期化疗/化学免疫治疗(±放疗)的第1-4周期后进行,用于预后判断和早期治疗升级或降级,即应答或风险适应治疗。定量PET指标(如SUV、代谢肿瘤体积、总病灶糖酵解及其治疗变化)正被研究作为更可重复且可能更准确的应答和预后预测因子,但阳性预测值有限等挑战仍存。
要点
- PET/CT常规用于霍奇金淋巴瘤分期和治疗结束时的疗效评估。
- 中期PET/CT在6-8周期化疗/化学免疫治疗(±放疗)的第1-4周期后用于预后判断和应答或风险适应治疗。
- 定量PET指标(SUV、代谢肿瘤体积、总病灶糖酵解)正被研究作为应答和预后预测因子,但阳性预测值有限。
核心结论
- 18F-FDG-PET/CT是霍奇金淋巴瘤检查和治疗管理的重要组成部分,常规用于分期和末次治疗后疗效评估。
- 中期PET/CT用于预后判断和早期治疗升级或降级(应答或风险适应治疗)。
- 定量PET指标正被研究作为更可重复且可能更准确的应答和预后预测因子,但阳性预测值有限等挑战仍存。
- 本综述讨论了PET/CT用于免疫治疗疗效评估的价值。
研究设计与样本
- 本文为综述,总结PET/CT在霍奇金淋巴瘤中的主要应用、优势与局限性以及近期基于PET/CT指标的精准医学进展。
主要发现
- PET/CT目前常规用于霍奇金淋巴瘤分期和末次治疗后的疗效评估。
- 中期PET/CT通常在6-8周期化疗/化学免疫治疗(±放疗)的第1-4周期后进行,用于预后判断和潜在治疗升级或降级。
- SUV、代谢肿瘤体积、总病灶糖酵解及其治疗变化等定量指标正被研究作为更可重复且可能更准确的应答和预后预测因子。
- 尽管PET/CT在淋巴瘤中的使用标准化已取得进展,挑战仍存,尤其是其阳性预测值有限。
关键数值与推荐
- 中期PET/CT通常在6-8周期化疗/化学免疫治疗(±放疗)的第1-4周期后进行,用于预后判断和潜在治疗升级或降级。
临床怎么用
- 原文未据此给出推荐。
局限性
- 尽管PET/CT在淋巴瘤中的使用标准化已取得进展,挑战仍存,尤其是其阳性预测值有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
18F-FDG-PET/CT is now an integral part of the workup and management of patients with Hodgkin's lymphoma (HL). PET/CT is currently routinely performed for staging and for response assessment at the end of treatment. Interim PET/CT is typically performed after 1-4 of 6-8 chemo/chemoimmunotherapy cycles ± radiation for prognostication and potential treatment escalation or de-escalation early in the course of therapy, a concept known as response-or risk-adapted treatment. Quantitative PET is an area of growing interest. Metrics such as the standardized uptake value (SUV), metabolic tumor volume, total lesion glycolysis, and their changes with treatment are being investigated as more reproducible and, potentially, more accurate predictors of response and prognosis. Despite the progress made in standardizing the use of PET/CT in lymphoma, challenges remain, particularly with respect to its limited positive predictive value. This review highlights the most relevant applications of PET/CT in HL, its strengths and limitations, as well as recent efforts to implement PET/CT-based metrics as promising tools for precision medicine. Finally, the value of PET/CT for response assessment to immunotherapy is discussed.
引用
- Al-Ibraheem A, Mottaghy FM, Juweid ME, et al. PET/CT in Hodgkin Lymphoma: An Update. Semin Nucl Med. 2022. PMID: 36369090. doi:10.1053/j.semnuclmed.2022.10.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。